The respiratory syncytial virus fusion protein formulated with a novel combination adjuvant induces balanced immune responses in lambs with maternal antibodies

Vaccine

Volumn 33, Issue 11, 2015, Pages 1338-1344

  Garg, R ^a   Latimer, L ^a   Gerdts, V ^a,b   Potter, A ^a,b   Van Drunen Littel Van Den Hurk, S ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Animal model; Lambs; Maternal antibodies; Maternal immunization; Neonatal immunization; RSV

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT; MATERNAL ANTIBODY; NEUTRALIZING ANTIBODY; PALIVIZUMAB; POLYMER; POLYPHOSPHAZENE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE PLUS FUSION PROTEIN; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VITRO STUDY; LAMB; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SECRETORY CELL; VACCINATION; VIRUS NEUTRALIZATION; ANIMAL; BLOOD; DOMESTIC SHEEP; FEMALE; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; LUNG; MONONUCLEAR CELL; NEWBORN; PASSIVE IMMUNIZATION; PREGNANCY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LUNG; PREGNANCY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; SHEEP, DOMESTIC; VACCINATION; VIRAL FUSION PROTEINS; VIRAL VACCINES;

EID: 84924065107     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.041     Document Type: Article

References (21)

1. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005, 352:1749-1759.
2. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422-434.
3. Group TI-RS Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537.
4. Collins P.L., Graham B.S. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 2008, 82:2040-2055.
5. Vaux-Peretz F., Chapsal J.M., Meignier B. Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice. Vaccine 1992, 10:113-118.
6. Garlapati S., Garg R., Brownlie R., Latimer L., Simko E., Hancock R.E.W., et al. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. Vaccine 2012, 30:5206-5214.
7. Garg R., Latimer L., Simko E., Gerdts V., Potter A., van Drunen Littel-van den Hurk S. Induction of mucosal immunity and protection by intranasal immunisation with a novel respiratory syncytial virus vaccine formulation. J Gen Virol 2013, 95:301-306.
8. Garg R., Latimer L., Gerdts V., Potter A., van Drunen Littel-van den Hurk S. Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity. J Gen Virol 2014, 95:1043-1054.
9. Derscheid R.J., Ackermann M.R. Perinatal lamb model of respiratory syncytial virus (RSV) infection. Viruses 2012, 4:2359-2378.
10. Raggo C., Habermehl M., Babiuk L.A., Griebel P. The in vivo effects of recombinant bovine herpesvirus-1 expressing bovine interferon. J Gen Virol 2000, 81:2665-2673.
11. Delgado M.F., Coviello S., Monsalvo A.C., Melendi G.A., Hernandez J.Z., Batalle J.P., et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009, 15:34-41.
12. Ackermann M.R. Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments. Ilar J 2014, 55:4-15.
13. Sullivan V.J., Mikszta J.A., Laurent P., Huang J., Ford B. Noninvasive delivery technologies: respiratory delivery of vaccines. Expert Opin Drug Delivery 2006, 3:87-95.
14. Vujanic A., Wee J.L., Snibson K.J., Edwards S., Pearse M., Quinn C., et al. Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX adjuvanted recombinant antigens. Vaccine 2010, 28:2593-2597.
15. Wee J.L., Scheerlinck J.P., Snibson K.J., Edwards S., Pearse M., Quinn C., et al. Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing. Mucosal Immunol 2008, 1:489-496.
16. Cassetti M.C., Katz J.M., Wood J. Report of a consultation on role of immunological assays to evaluate efficacy of influenza vaccines. Initiative for Vaccine Research and Global Influenza Programme, World Health Organization, Geneva, Switzerland, 25 January 2005. Vaccine 2006, 24:541-543.
17. Weltzin R., Traina-Dorge V., Soike K., Zhang J.Y., Mack P., Soman G., et al. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis 1996, 174:256-261.
18. Murphy B.R., Walsh E.E. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988, 26:1595-1597.
19. Crowe J.E. Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines. Vaccine 1998, 16:1423-1432.
20. Welliver T.P., Garofalo R.P., Hosakote Y., Hintz K.H., Avendano L., Sanchez K., et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 2007, 195:1126-1136.
21. Johnson J.E., Gonzales R.A., Olson S.J., Wright P.F., Graham B.S. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 2007, 20:108-119. (An Official Journal of the United States and Canadian Academy of Pathology, Inc.).